HSP90B1 and breast cancer: Interestingly, the BC patients were divided into two groups with (N = 34, considered as PR-BC patients) or without (N = 33, considered as PS-BC patients) paclitaxel treatment history, and we surprisingly found that gp96 mRNA levels were apparently increased in the cancer tissues collected from BC patients with paclitaxel-resistant properties in contrast with the PS-BC patients (Fold changes: 1.92, Figure 1B).